FGL1 and cancer: Notably, Wang et al. introduced another ligand of LAG-3, Fibrinogen-like protein 1 (FGL1), and suggested a potential new target in cancer immunotherapy, the FGL1/LAG-3 pathway (Wang et al., 2019).